Impact of subsequent chemotherapy on the survival of elderly patients with extensive stage small cell lung cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Eun Joo | - |
dc.contributor.author | Choi, Yoon Ji | - |
dc.contributor.author | Lee, Se Ryeon | - |
dc.contributor.author | Sung, Hwa Jung | - |
dc.contributor.author | Kim, Jung Sun | - |
dc.date.accessioned | 2021-08-30T09:48:48Z | - |
dc.date.available | 2021-08-30T09:48:48Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-11 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/52045 | - |
dc.description.abstract | Background/Aims: The prognosis of small cell lung cancer (SCLC) is still poor because of rapid recurrence, despite good response to initial chemotherapy. Additionally, patients' old ages and comorbidities are often obstacles that make it difficult to apply subsequent treatment after initial treatment. This retrospective study analyzed the correlation of post-progression survival (PPS) with overall survival (OS), and prognostic factors including comorbidities to figure out impact of subsequent chemotherapy on OS in elderly extensive disease SCLC. Methods: We analyzed 101 patients of age 65 years or older who were recently diagnosed with extensive disease SCLC (ED-SCLC) in Korea University Medical Center between January 1995 and December 2015. The degree of comorbidity was scored using simplified comorbidity score (SCS). Correlation between PPS, progression-free survival (PFS) and OS was analyzed using a Pearson correlation coefficient. Cox proportional hazards regression was employed to examine the influence of clinical variables on survival. Results: Median age of patients was 71 years old (range, 65 to 83). Median OS was 8.7 months (range, 0.3 to 42.7). PPS was a reliable factor on OS than PFS (R-2 = 0.852, p < 0.001). Prognostic factors associated with improved survival were SCS < 9, administration > 4 cycles of first line chemotherapy and subsequent second line chemotherapy. Conclusions: PPS was more correlated with OS than PFS in elderly patients with ED-SCLC. The most important prognostic factors for PPS and OS included SCS and second line chemotherapy. Patients receiving subsequent treatment had increased OS regardless of degree of comorbidity. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ASSOC INTERNAL MEDICINE | - |
dc.subject | POST-PROGRESSION SURVIVAL | - |
dc.subject | SIMPLIFIED COMORBIDITY SCORE | - |
dc.subject | POSTPROGRESSION SURVIVAL | - |
dc.subject | CLINICAL IMPACT | - |
dc.subject | TUMOR RESPONSE | - |
dc.title | Impact of subsequent chemotherapy on the survival of elderly patients with extensive stage small cell lung cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kang, Eun Joo | - |
dc.contributor.affiliatedAuthor | Choi, Yoon Ji | - |
dc.identifier.doi | 10.3904/kjim.2019.136 | - |
dc.identifier.scopusid | 2-s2.0-85095433535 | - |
dc.identifier.wosid | 000583746600021 | - |
dc.identifier.bibliographicCitation | KOREAN JOURNAL OF INTERNAL MEDICINE, v.35, no.6, pp.1468 - 1476 | - |
dc.relation.isPartOf | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.citation.title | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.citation.volume | 35 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1468 | - |
dc.citation.endPage | 1476 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002638180 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | POST-PROGRESSION SURVIVAL | - |
dc.subject.keywordPlus | SIMPLIFIED COMORBIDITY SCORE | - |
dc.subject.keywordPlus | POSTPROGRESSION SURVIVAL | - |
dc.subject.keywordPlus | CLINICAL IMPACT | - |
dc.subject.keywordPlus | TUMOR RESPONSE | - |
dc.subject.keywordAuthor | Small cell lung cancer | - |
dc.subject.keywordAuthor | Comorbidity | - |
dc.subject.keywordAuthor | Prognosis | - |
dc.subject.keywordAuthor | Chemotherapy | - |
dc.subject.keywordAuthor | Post-progression survival | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.